Skip to main content
. 2014 Jan 13;32(6):587–600. doi: 10.1200/JCO.2013.48.7934

Fig 1.

Fig 1.

Treatment algorithm for elderly patients with multiple myeloma (MM). MEL 100, melphalan 100 mg/m2; MEL 200, melphalan 200 mg/m2; MPR-R, melphalan-prednisone-lenalidomide followed by lenalidomide; MPT, melphalan-prednisone-thalidomide; Rd, lenalidomide plus low-dose dexamethasone; Vd, bortezomib-dexamethasone; VCD, bortezomib-cyclophosphamide-dexamethasone; VMP, bortezomib-melphalanprednisone; VMPT-VT, bortezomibmelphalan-prednisone-thalidomide followed by bortezomib-thalidomide; VRD, bortezomib-lenalidomide-dexamethasone.